US4605669A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Lipoxygenase inhibiting naphthohydroxamic acids
Assignee: Abbott Laboratories
•
Filing: 1985-04-26
•
Granted: 1986-08-12
•
Expires: 2005-04-26
Abstract
Abstract Compounds of the formula <IMAGE> where R1 is H, or C1 to C6 alkyl; R2 is selected from C1 to C22 alkyl, cycloalkyl, aralky or alkenyl; and M is a pharmaceutically acceptable cation, are potent inhibitors of the enzymes 5-, 12- and 15-lipoxygenase.
Inventors
- 👤 James B. Summers, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 01:07
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/16; A61K31/165; A61P; A61P11/00; A61P17/00; A61P29/00; A61P37/00; A61P37/08; A61P43/00
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
40 words
A compound of the formula ##STR4## where R 1 is H, or C 1 to C 6 alkyl; R 2 is selected from C 1 to C 22 alkyl, cycloalkyl, aralcy or alkenyl; and M is a pharmaceutically acceptable cation.
Claim 2
Dependent Claim
40 words
A compound of the formula ##STR4## where R 1 is H, or C 1 to C 6 alkyl; R 2 is selected from C 1 to C 22 alkyl, cycloalkyl, aralcy or alkenyl; and M is a pharmaceutically acceptable cation.
Claim 3
Dependent Claim
16 words
A compound according to claim 1 wherein R 2 is C 2 to C 6 alkyl.
Claim 4
Dependent Claim
16 words
A compound according to claim 2 wherein R 1 is C 1 to C 6 alkyl.
Claim 5
Dependent Claim
36 words
A compound according to claim 1 wherein the pharmaceutically acceptable cation is a nontoxic cation selected from the group consisting of hydrogen, alkali metal cations, alkaline earth metal cations, and ammonium, quaternary ammonium and amine cations.
Claim 6
Dependent Claim
44 words
A method of inhibiting lipoxygenase activity in a human or lower animal host in need of such treatment, comprising administering to the human or lower animal host a compound according to claim 1 in an amount effective to inhibit lipoxygenase activity in the host.
Claim 7
Dependent Claim
15 words
A method according to claim 5 wherein the compound is administered orally, parenterally, or topically.
Claim 8
Dependent Claim
24 words
A method according to claim 6 wherein the compound is administered at a dosage of from 0.001 to 100 mg/kg body weight per day.
Claim 9
Dependent Claim
24 words
A method according to claim 7 wherein the compound is administered at a dosage of from 0.01 to 10 mg/kg body weight per day.
Claim 10
Dependent Claim
31 words
A composition in unit dosage form for the inhibition of lipoxygenase activity in a human or lower animal host, comprising a compound according to claim 1 and a pharmaceutical carrier material.
References Cited (Backward Citations)
US2397508A
Cited
FR1548641A
Cited
US3819702A
Cited
US3900514A
Cited
US3968145A
Cited
US3978116A
Cited
US4109013A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-08-11 | 1990-02-10 | 1990-08-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-08-11 | 1994-02-10 | 1994-08-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-08-11 | 1998-02-10 | 1998-08-12 | $7700.00 | Window Closed / Lapsed |